1. Home
  2. BDSX vs JCE Comparison

BDSX vs JCE Comparison

Compare BDSX & JCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Biodesix Inc.

BDSX

Biodesix Inc.

HOLD

Current Price

$6.85

Market Cap

62.5M

Sector

Health Care

ML Signal

HOLD

Logo Nuveen Core Equity Alpha Fund of Beneficial Interest

JCE

Nuveen Core Equity Alpha Fund of Beneficial Interest

HOLD

Current Price

$15.99

Market Cap

269.8M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
BDSX
JCE
Founded
2005
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Precision Instruments
Trusts Except Educational Religious and Charitable
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
62.5M
269.8M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
BDSX
JCE
Price
$6.85
$15.99
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$32.50
N/A
AVG Volume (30 Days)
66.8K
49.7K
Earning Date
11-03-2025
01-01-0001
Dividend Yield
N/A
9.26%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$80,173,000.00
N/A
Revenue This Year
$20.75
N/A
Revenue Next Year
$25.05
N/A
P/E Ratio
N/A
N/A
Revenue Growth
22.29
N/A
52 Week Low
$3.44
$11.64
52 Week High
$31.20
$14.28

Technical Indicators

Market Signals
Indicator
BDSX
JCE
Relative Strength Index (RSI) 42.84 55.76
Support Level $6.56 $15.47
Resistance Level $7.03 $16.12
Average True Range (ATR) 0.57 0.17
MACD -0.13 0.02
Stochastic Oscillator 26.44 76.47

Price Performance

Historical Comparison
BDSX
JCE

About BDSX Biodesix Inc.

Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.

About JCE Nuveen Core Equity Alpha Fund of Beneficial Interest

Nuveen Core Equity Alpha Fund is a diversified closed-end management investment company. Its investment objective is to provide an attractive level of total return, through long-term capital appreciation and through income and gains. The Fund invests in a portfolio of actively managed large-capitalization U.S. common stocks, using the sub-adviser's proprietary quantitative process designed to provide the potential for long-term outperformance. Additionally, the Fund seeks to reduce the volatility of its returns relative to the returns of the Equity Portfolio over extended periods by writing (selling) index call options and/or call options on custom baskets of securities.

Share on Social Networks: